US 12,291,553 B2
Non-opioid anti-pain medication
Fernanda Laezza, Galveston, TX (US); Jia Zhou, Galveston, TX (US); Jin Mo Chung, Galveston, TX (US); Pingyuan Wang, Galveston, TX (US); Jun-Ho La, Galveston, TX (US); Oluwarotimi Folorunso, Galveston, TX (US); and Aditya Singh, Galveston, TX (US)
Appl. No. 17/425,688
Filed by The Board of Regents of The University of Texas System, Austin, TX (US)
PCT Filed Jan. 24, 2020, PCT No. PCT/US2020/015079
§ 371(c)(1), (2) Date Jul. 23, 2021,
PCT Pub. No. WO2020/154679, PCT Pub. Date Jul. 30, 2020.
Claims priority of provisional application 62/796,916, filed on Jul. 23, 2021.
Prior Publication US 2022/0185855 A1, Jun. 16, 2022
Int. Cl. C07K 14/50 (2006.01); A61K 38/00 (2006.01); A61P 25/04 (2006.01); C07K 5/117 (2006.01)
CPC C07K 14/50 (2013.01) [A61P 25/04 (2018.01); C07K 5/1024 (2013.01); A61K 38/00 (2013.01)] 19 Claims
 
1. A compound of Formula I or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein: R1 is H, alkyl, cycloalkyl, aryl, heteroaryl, R4CO—, R5NHCO—, R6OCO—, R7SO2—, or fluorenylmethoxycarbonyl protecting group (Fmoc);
wherein R4, R5, R6 and R7 are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, adamantyl, and benzyl, and each of R4, R5, R6 and R7 is optionally substituted with one or more substituents selected from the group consisting of —OH, —CN, —NH2, and halogen;
R2 is alkyl, aryl, heteroaryl, or cycloalkyl; and
R3 is OH, alkoxy, allyloxy,

OG Complex Work Unit Chemistry
or —NR8R2, wherein R8 and R9 are independently selected from the group consisting of H, alkyl, aryl and heteroaryl; or R8 and R9 are optionally joined together to form a N-containing heterocycle with 1-3 heteroatoms.